Compare BNGO & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | POM |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Other Specialty Stores |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 11.3M |
| IPO Year | 2018 | 2021 |
| Metric | BNGO | POM |
|---|---|---|
| Price | $1.20 | $0.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 128.2K | 99.5K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $14.99 | N/A |
| Revenue Next Year | $34.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.00 | $0.06 |
| 52 Week High | $5.50 | $6.43 |
| Indicator | BNGO | POM |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 52.53 |
| Support Level | $1.10 | $0.17 |
| Resistance Level | $1.31 | $1.15 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 86.84 | 64.34 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.